ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

COG Cambridge Cognition Holdings Plc

48.00
0.00 (0.00%)
10 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Cambridge Cognition Holdings Plc LSE:COG London Ordinary Share GB00B8DV9647 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 48.00 47.00 49.00 48.00 48.00 48.00 19,972 07:31:25
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 12.61M -409k -0.0117 -41.03 16.73M

Cambridge Cognition Holdings PLC New client signs with Cognition Kit software (7369P)

31/05/2018 7:00am

UK Regulatory


Cambridge Cognition (LSE:COG)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Cambridge Cognition Charts.

TIDMCOG

RNS Number : 7369P

Cambridge Cognition Holdings PLC

31 May 2018

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

New client signs with Cognition Kit software

The digital neuroscience company Cambridge Cognition Holdings plc, (AIM: COG, 'the Company'), which develops and markets digital solutions to assess brain health, has announced a new $0.5m contract with a major pharmaceutical company for the use of its Cognition Kit(TM) digital health software in a clinical trial.

Cognition Kit measures cognitive health on mobile and wearable devices, enabling researchers to gather data in everyday life and clinicians to make more insightful treatment decisions for their patients.

This clinical trial will monitor patients diagnosed with a neurological condition for 12 months. During this time, participants will use a Cognition Kit smartphone app to test their brain health remotely and frequently, providing the sponsor with rich real-world data outside of clinical sites in a more holistic, cost-effective and patient-centric fashion.

The new contract follows the Company's successful collaborations with existing Cognition Kit partners and further negotiations with other major pharmaceutical companies are at an advanced stage.

Dr Steven Powell, Chief Executive Officer, at Cambridge Cognition said: "The pharmaceutical industry is increasingly looking to develop novel biomarkers and use digital phenotyping techniques to improve their data intelligence and market access. Having successfully demonstrated the effectiveness of Cognition Kit technology through our ongoing partnership with Takeda, we are delighted to be signing additional clients with whom we expect to establish long-lasting commercial partnerships."

Enquiries

 
 Cambridge Cognition Holdings PLC 
  Steven Powell, Chief Executive          Tel: 01223 810 
  Officer                                 700 
  Noah Konig, Director of Marketing       press@camcog.com 
 finnCap Ltd (NOMAD and Joint Broker)   Tel: 020 7220 
  Geoff Nash / Simon Hicks               0500 
  Alice Lane                             (Corporate Finance) 
                                         (Corporate Broking) 
 Dowgate Capital Stockbrokers Limited   Tel: 020 3903 
  (Joint Broker)                         7715 
  David Poutney / James Serjeant 
 IFC Advisory Ltd (Financial PR         Tel: 020 3934 
  and IR)                                6630 
  Graham Herring / Miles Nolan / 
  Zach Cohen 
 

About Cognition Kit Limited

Cognition Kit is a joint venture between Cambridge Cognition and Ctrl Group formed to develop scientifically valid digital health apps on mobile and wearable devices. Cognition Kit software takes research out of the lab and into everyday life, enabling doctors, scientists and the public to better understand and manage brain health.

For further information visit www.cognitionkit.com

About Cambridge Cognition Holdings PLC

Cambridge Cognition is a digital neuroscience company developing software products to better understand, detect and treat brain health conditions. The company's cognitive technologies are used to accelerate the research and development of new treatments, enhance understanding of the brain and accurately assess cognitive health in patients worldwide.

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

CNTSDSFISFASEDI

(END) Dow Jones Newswires

May 31, 2018 02:00 ET (06:00 GMT)

1 Year Cambridge Cognition Chart

1 Year Cambridge Cognition Chart

1 Month Cambridge Cognition Chart

1 Month Cambridge Cognition Chart

Your Recent History

Delayed Upgrade Clock